The functional role of IL-1 family member 10, recently renamed IL-38, remains unknown. In the present study we aimed to elucidate the biological function of IL-38 and to identify its receptor. Heat-killed Candida albicans was used to stimulate memory T-lymphocyte cytokine production in freshly obtained human peripheral blood mononuclear cells from healthy subjects. The addition of recombinant IL-38 (152 amino acids) inhibited the production of T-cell cytokines IL-22 (37% decrease) and IL-17 (39% decrease). The reduction in IL-22 and IL-17 caused by IL-38 was similar to that caused by the naturally occurring IL-36 receptor antagonist (IL-36Ra) in the same peripheral blood mononuclear cells cultures. IL-8 production induced by IL-36γ was reduced by IL-38 (42% decrease) and also was reduced by IL-36Ra (73% decrease). When human blood monocyte-derived dendritic cells were used, IL-38 as well as IL-36Ra increased LPS-induced IL-6 by twofold. We screened immobilized extracellular domains of each member of the IL-1 receptor family, including the IL-36 receptor (also known as "IL-1 receptor-related protein 2") and observed that IL-38 bound only to the IL-36 receptor, as did IL-36Ra. The dose-response suppression of IL-38 as well as that of IL-36Ra of Candida-induced IL-22 and IL-17 was not that of the classic IL-1 receptor antagonist (anakinra), because low concentrations were optimal for inhibiting IL-22 production, whereas higher concentrations modestly increased IL-22. These data provide evidence that IL-38 binds to the IL-36R, as does IL-36Ra, and that IL-38 and IL-36Ra have similar biological effects on immune cells by engaging the IL-36 receptor.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286950PMC
http://dx.doi.org/10.1073/pnas.1121534109DOI Listing

Publication Analysis

Top Keywords

il-36 receptor
24
receptor antagonist
12
il-38
11
receptor
9
il-38 binds
8
biological effects
8
effects immune
8
immune cells
8
peripheral blood
8
blood mononuclear
8

Similar Publications

Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab.

Clin Cosmet Investig Dermatol

January 2025

Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, People's Republic of China.

Generalized Pustular Psoriasis (GPP) is a rare, severe, life-threatening form of psoriasis and often resistant to conventional systemic therapy. It can be induced by deficiency of interleukin (IL)-36 receptor antagonist. Treatment of patients with GPP is often difficult, and there is no consensus on the best options available to date.

View Article and Find Full Text PDF

Background: Interleukin (IL)-38 is an IL-1 family cytokine that was proposed to exert anti-inflammatory effects. However, its mechanisms of action are not well understood and the identity of the IL-38 receptor(s) remains debated. Proposed candidates include the IL-1 receptor (IL-1R1), the IL-36 receptor (IL-36R) and the orphan receptor IL-1RAPL1.

View Article and Find Full Text PDF

Background: Idiopathic granulomatous mastitis (IGM) is a chronic inflammatory disorder characterised by the formation of non-caseating granulomas in breast tissue, primarily affecting young women of childbearing age. The aetiology of IGM remains unclear, with potential factors including trauma, hormonal influences, and autoimmune responses. Recent studies suggest that immune dysregulation may play a critical role in IGM, highlighting the need for exploration of biomarkers involved in inflammation and immune modulation, particularly LL-37, galectin-3, IL-36, and TLR3.

View Article and Find Full Text PDF
Article Synopsis
  • Generalized pustular psoriasis (GPP) is a severe skin disease that can be life-threatening, and spesolimab is an IL-36 receptor antibody showing promise for treating it, especially in adults, though data for children are limited.
  • The study involved five young patients (4-12 years old) who received a single dose of spesolimab, with significant improvements in their skin condition observed just one week later.
  • All patients showed decreased levels of key inflammatory markers and no recurrence of symptoms was noted after treatment, suggesting that spesolimab could be a potential treatment option for children with GPP.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!